

GRESHAM HOUSE INCOME & GROWTH VCT PLC ("the Company")

LEI: 213800FPC15FNM74YD92

7 April 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

Further to the Company's Allotment of Shares and Total Voting Rights announcement on 1 April 2026 in respect of the allotment of new Ordinary Shares pursuant its offer for subscription published on 2 February 2026, and following the admission to trading of those new Ordinary Shares, the following additional information is disclosed in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer	
a)	Name	Gresham House Income & Growth VCT plc
b)	LEI	213800FPC15FNM74YD92
2	Details of the transferable securities admitted to trading	
a)	Name, type and identification code	Ordinary Shares of 1p each ISIN: GB00B29BN198
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities admitted	44,745,151
d)	Total number of securities in issue following admission	361,717,741
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details	
a)	Date of admission	7 April 2026
b)	Prospectus information	Prospectus: 2 February 2026 https://greshamhouse.com/strategic-equity/private-equity/the-gresham-house-vcts/gresham-house-income-growth-vct-plc/
c)	Coverage of notification	The admission on 7 April 2026
4	Contact details	
a)	Name and contact number	Gresham House Asset Management Limited Company Secretary Telephone: 020 7382 0999

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ADMEAFLXEFKKEFA